Shell Asset Management Co. Decreases Position in United Therapeutics Corporation $UTHR

Shell Asset Management Co. cut its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 83.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 394 shares of the biotechnology company’s stock after selling 1,917 shares during the period. Shell Asset Management Co.’s holdings in United Therapeutics were worth $165,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Wilmington Savings Fund Society FSB boosted its holdings in United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 49 shares during the period. Abich Financial Wealth Management LLC bought a new stake in United Therapeutics in the third quarter valued at approximately $44,000. WealthCollab LLC boosted its stake in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares during the period. Rakuten Securities Inc. grew its holdings in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares during the last quarter. Finally, True Wealth Design LLC increased its stake in shares of United Therapeutics by 738.5% in the third quarter. True Wealth Design LLC now owns 109 shares of the biotechnology company’s stock worth $46,000 after buying an additional 96 shares during the period. 94.08% of the stock is owned by institutional investors.

Insider Activity

In related news, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $474.65, for a total value of $10,679,625.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction dated Thursday, February 5th. The stock was sold at an average price of $483.25, for a total transaction of $4,010,975.00. Following the sale, the executive vice president directly owned 36,781 shares in the company, valued at $17,774,418.25. The trade was a 18.41% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 450,714 shares of company stock worth $218,011,238. Corporate insiders own 10.30% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Royal Bank Of Canada increased their price target on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research report on Thursday, October 30th. Morgan Stanley set a $447.00 price target on United Therapeutics in a report on Wednesday, October 29th. Wells Fargo & Company upped their price target on United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research report on Thursday, October 30th. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $575.00 target price on shares of United Therapeutics in a research note on Wednesday, November 19th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $509.50.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $476.05 on Thursday. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $519.99. The firm has a market capitalization of $20.50 billion, a P/E ratio of 18.04, a P/E/G ratio of 2.57 and a beta of 0.85. The stock has a 50 day moving average price of $485.84 and a 200-day moving average price of $437.55.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.